Hims & Hers’ $250M buyback fails to halt plunging stock price
Hims & Hers Health has struggled to regain investor trust despite a major stock market buyback. The company’s $250 million repurchase programme, announced in mid-November 2025, failed to stop a sharp decline in its stock market price. Within a month, shares fell by 30%, raising concerns about its financial health. On November 17, 2025, the company’s board approved a $250 million share repurchase plan. This followed an earlier $100 million buyback that had already been completed. Yet, the stock market continued to drop, signalling persistent doubts among investors. The failed stock market buyback and ongoing stock market decline highlight the challenges facing Hims & Hers Health. With analysts largely advising caution and insiders offloading shares, the company’s high valuation remains under scrutiny. The coming months will likely determine whether investor confidence can recover or if further declines lie ahead.
